PharmaTher Holdings Ltd. is a specialty pharmaceutical company dedicated to developing and commercializing ketamine-based pharmaceuticals, addressing significant unmet medical needs in anesthesia, sedation, pain, mental health, and neurological disorders. Its flagship product, KETARX™, is a proprietary formulation of ketamine hydrochloride injection, under development for indications such as anesthesia, procedural sedation, Parkinson’s disease, amyotrophic lateral sclerosis, and complex regional pain syndrome. PharmaTher is also pioneering innovative delivery methods, including ketamine microneedle patches designed to enable patients to safely self-administer treatment remotely, with features focused on anti-tampering and anti-abuse. The company has a strategic interest in capturing regulatory incentives from the FDA, such as orphan drug and fast track designations. In addition, PharmaTher owns a minority stake in Sairiyo Therapeutics, advancing cepharanthine for infectious disease and cancer indications. Through a combination of clinical-stage research and targeted product development, PharmaTher Holdings Ltd. aims to establish a leadership role in the evolving field of psychedelic and specialty pharmaceutical therapies for transformative patient care.